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Abstract:  
Background: Wilson’s disease (WD), an inborn error of copper metabolism caused by mutations in the 
ATPase copper transporting beta (ATP7B) gene, manifests variable age of onset and different 
degrees of hepatic and neurological disturbances. This complex phenotypical outcome of a classical 
monogenic disease can possibly be explained by modifier loci regulating the clinical course of the 
disease. The brain-derived neurotropic factor (BDNF), critical for the survival, morphogenesis and 
plasticity of the neurons, and the dopamine receptor D2 (DRD2), one of the most abundant dopamine 
receptors in the brain, have been highlighted in the pathophysiology of various neuropsychiatric 
diseases. This study aims to identify the potential association between BDNF and DRD2 gene 
polymorphisms and WD and its clinical characteristics. 
Methods: A total of 164 WD patients and 270 controls from India were included in this study. Two 
BDNF polymorphisms [p.Val66Met (c.G196A) and c.C270T] and the DRD2 Taq1A (A2/A1 or C/T) 
polymorphism were examined for their association with WD and some of its clinical attributes, using 
polymerase chain reaction, restriction fragment length digestion and bidirectional sequencing.  
Results: The C allele and CC genotype of BDNF C270T were significantly overrepresented among 
controls compared to WD patients. In addition, a significantly higher proportion of the allele coding for 
Val and the corresponding homozygous genotype of BDNF Val66Met polymorphism was found 
among WD patients with age of onset later than 10 years. Furthermore, the A1A1 genotype of DRD2 
Taq1A polymorphism was significantly more common among WD patients with rigidity.  
Conclusion: Our data suggest that both BDNF and DRD2 may act as potential modifiers of WD 
phenotype in the Indian context.  
Key words: BDNF, DRD2, Wilson’s disease, WD 
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Introduction:   
Wilson’s disease (WD) is an autosomal recessive disorder of copper metabolism caused by 
mutations in the ATPase copper transporting beta (ATP7B) gene, which encodes a copper-
transporting P-type ATPase primarily expressed in liver and brain. A broad spectrum of 
mutations in ATP7B leads to toxic deposition of copper in liver and brain giving rise to a 
wide-range of hepatic and neurological features, such as, low plasma ceruloplasmin level, 
high urinary copper, dystonia, Parkinsonism, gait disturbances, rigidity along with Kayser 
Fleischer ring (K - F ring) (Das and Ray, 2006). A large number of mutations have been 
reported in ATP7B (Todorov et al, 2016). Interestingly significant phenotypic variation has 
been noticed between monozygotic twins with the same ATP7B mutation highlighting the 
potential involvement of modifier loci (Kegleyet al, 2010). Potential modifier genes, such as, 
apolipoprotein E (APOE), human prion related protein (PRNP), methylenetetrahydrofolate 
reductase (MTHFR) and divalent metal transporter 1 (DMT1) have been proposed to be 
associated with the clinical course of the disease (Kieffer and Medici V, 2017).  
Brain derived neurotrophic factor (BDNF), is essential for differentiation and survival of the 
neurons, modulating synaptic plasticity and synaptic transmission (Mizui et al, 2014). It 
regulates long term potentiation and long term depression functions in the hippocampal and 
cortical neurons, thus affecting learning and memory (Mizui et al, 2015). Metal ions may 
influence the BDNF activity and it is well known that the alteration of Cu2+ homeostasis is a 
prominent factor in the development of neuropathologies (Travaglia et al, 2012). BDNF is 
initially synthesized as a precursor protein (i.e. prepro-BDNF) in the endoplasmic reticulum. 
Following cleavage of the signal peptide, pro-BDNF is converted to mature BDNF and BDNF 
pro-peptide. BDNF as dimer binds to two receptors of distinct classes: the type B tyrosine 
kinase receptor of the tropomyosin-related kinase family (TrkB) and the p75 receptor, which 
is a member of the tumor necrosis factor (TNF) receptor family (Mizui et al, 2014). Previous 
reports suggest that BDNF polymorphisms and reduced BDNF expression in human brains 
are closely related to the pathogenesis of several neurodegenerative and neuropsychiatric 
disorders (Autry and Monteggia, 2012).  
 
A common single-nucleotide polymorphism (SNP) in BDNF, rs6265 (c.G196A), which results 
in a change of valine to methionine amino acid at codon 66,presents in the pro-domain 
region of the BDNF pro-peptide serving as a bioactive molecule for neurons. This SNP has 
been associated with abnormalities in memory, learning and neuropsychiatric functions 
(Mizui et al, 2015; Mizui et al, 2017). A functional promoter polymorphism, rs56164415 
(c.C270T) of the BDNF gene has been extensively studied in schizophrenia and Alzheimer’s 
disease (Watanabe et al, 2013). Bioinformatics analysis revealed that C>T substitution 
causes loss of transcription factor binding, which may alter the transcriptional efficacy 
(Catharius et al, 2005).  
 
Dopamine receptor D2 (DRD2) is encoded by the DRD2 gene, which is located on 
chromosome 11q22.2 in humans (Klein et al, 1999). Reduced striatal dopamine levels have 
been observed in WD patients (Nyberg et al, 1982). Animal studies have indicated 
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decreased DRD2 expression during copper overloading (De Vries et al, 1986). Single photon 
emission computerized tomography (SPECT) and positron emission tomography (PET) 
studies have shown postsynaptic loss of dopamine D2 receptors in striatum of WD patients 
(Oder et al, 1996, Westermark et al, 1996). Interestingly, WD patients also exhibit reduced 
bindings of dopamine ligands to dopamine receptors on lymphocytes probably due to 
damaged dopamine receptors resulting from copper toxicity (Członkowska et al, 1987). 
DRD2 has been found to be associated with Parkinson’s disease, dystonia, addiction and 
schizophrenia (Noble et al, 2003).  
The Taq1A polymorphism (dbSNP rs1800497; A2/A1 or C/T), located ~9.5 kb downstream 
from DRD2 in exon 8 of ankyrin repeat and kinase domain containing 1 (ANKK1) gene, has 
been investigated extensively (Blum et al, 2017) in neurological diseases. The A1 (T) allele 
of this polymorphism has been associated with reduced density of striatal dopamine D2 
receptors and has been associated with increased risk of Alzheimer’s disease among 
African Americans (Blum et al, 2017).It is worth mentioning that the Hap-Map project 
revealed that the studied Taq1A polymorphism, although present in the exon 8 of ANKK1 
gene, downstream of DRD2 locus, is in linkage disequilibrium (LD) with other DRD2 variants 
but not with any of the ANKK1polymorphisms, and has therefore been considered to have 
regulatory implications for DRD2 expression (Munafo et al, 2007).  
So far, about 150 ATP7B mutations have been identified in Indian WD patients 
(http://www.igdd.iicb.res.in/IGDD/home.aspx). Interestingly, a Copper metabolism MURR1 
domain containing protein 1 (COMMD1) mutation has been associated with abnormally high 
urinary copper in one patient (Gupta et al, 2010). Again, we have found association of APOE 
and PRNP polymorphisms as modifiers of susceptibility and clinical features among Indian 
WD patients (Roy et al, 2017). However, all the variable clinical features of WD cannot be 
explained on the basis of these genes. The roles of BDNF and DRD2 polymorphisms have 
not been tested among Indian WD patients for their potential to modify the clinical course of 
WD. Hence, the objective of this study was to test the association between genetic variations 
in BDNF and DRD2 with the susceptibility and clinical features of WD in the Indian context. 
 
Materials and Methods: 
Study Subjects: A total of 164 symptomatic unrelated WD patients comprising of 60 female 
and 104 male individuals participated in this study. Clinical and biochemical evaluations of 
the patients were performed at the Bangur Institute of Neurosciences, Kolkata; the National 
Medical College, Kolkata, West Bengal, India (n = 142); and the King Edward Memorial 
Hospital, Pune, Maharashtra, India (n = 22) as previously described (Mukherjee et al, 2014). 
A total of 270 healthy individuals (58 female and 212 male)lacking any personal or family 
history of neurological diseases, collected from general population from Kolkata, India 
served as controls. The controls and WD patients were mostly from the Indo-European 
linguistic group. Informed written consent was provided by all the participants. WD patients’ 
blood collection, DNA isolation and screening of ATP7Bwere done previously as described 
(Mukherjee et al, 2014). The diagnosis of WD patients was done following Sternleib’s criteria 
(Sternleib, 1990). Decreased serum ceruloplasmin level, elevated urinary copper, presence 
of Kayser Fleischer Ring, abnormal hepatic functioning, motor and neuropsychiatric deficits 
were taken as the key features to identify a WD patient. Neurological features include the 
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presence of dystonia, tremor, rigidity, gait disturbances, drooling, dysphagia, dysarthria and 
psychiatric disturbances. Neuropsychiatric signs and symptoms were evaluated by our 
clinical collaborators using detailed questionnaires and performance based tasks. The mean 
age ± standard deviation (S.D.) of the WD patients selected for our study was 11.68 ± 5.61 
years, ranging from 1.5 to 30 years. Age at onset of symptoms of WD was documented 
based on patients’ history and available medical records. The median age ± S.D. of the 
control subjects was 46 ± 8.5 years, ranging from 21 years to 76 years.  
BDNF and DRD2 polymorphism: Genotyping of two polymorphisms in the BDNF gene, i.e. 
rs6265 (p.Val66Met/ c.G196A) and rs56164415 (c.C270T), and rs1800497 (Taq1A; A2/A1or 
C/T) of the DRD2/ANKK1 were performed by polymerase chain reaction (PCR) followed by 
restriction enzyme digestion. PCR was carried out in 20 µL reaction volume using 80 ng of 
total genomic DNA with Go Taq Green PCR master mix (Promega, India) using specific 
primers for BDNF and DRD2/ANKK1 (Supplementary Table 1). All the PCR products were 
electrophoresed in 6% polyacrylamide gel; the amplicons were detected after ethidium 
bromide (EtBr) staining. The PCR amplicons for BDNF (rs6265 and rs56164415) and 
DRD2/ANKK1 (rs1800497) were further subjected to restriction digestion using New England 
Biolab (NEB) enzymes incubating at optimum temperature for 3 hours (Supplementary Table 
1). The digested products were electrophoresed on 7% polyacrylamide gel. The genotypes 
for 25% of the samples were further confirmed using bidirectional Sanger sequencing 
(ABI3130XL; Applied Biosystems, Foster City, CA). The details of sequencing primers are 
available on request. 
Statistical Analysis: Allele and genotype frequencies among patients and controls for the 
BDNF Val66Met and C270T polymorphisms and the DRD2/ANKK1 Taq1A polymorphism 
was compared by 2 X 2 contingency Chi-square analysis (95% CI) using JAVASTAT 
(http://statpages.info/ctab2x2.html) and Quantpsy software 
(http://www.quantpsy.org/chisq/chisq.htm). The p value <0.05 from Fisher Exact test was 
considered to be significant variation within the groups categorized on variable phenotypes 
of WD patients. A two tailed student’s t-test has been performed to compare between the 
mean ages of the WD patients carrying at least one A (methionine) allele and GG (Val/Val) 
homozygous genotype for rs6265 (val66met) polymorphism of BDNF gene.  In addition, 
logistic regression analysis was performed using Logistic regression calculating page 
(statpages.info/logistic.htm) to evaluate the possible association between independent 
variables (BDNF and DRD2 genotypes, age and sex) and age at onset of symptoms among 
WD patients and rigidity. Bonferroni corrections were applied to adjust for multiple testing. 
 
Results: 
Comparing the allelic and genotypic distribution of BDNF and DRD2 polymorphisms among 
164 WD patients and 270 controls revealed that the C allele [p – Value: 0.027; OR (95% CI) 
0.666 (0.489 - 0.907)] and CC genotype [p–Value: 0.010; OR (95% CI) 0.533 (0.352 – 
0.806)] of BDNF C270T polymorphism are likely to have protective role, being significantly 
overrepresented among controls. Our study also revealed a significant association of DRD2 
Taq1A polymorphism, where A1A1 genotype [p–Value: 0.018; OR (95% CI) 2.307 (1.236 – 
4.317)] were significantly overrepresented among WD patients compared to controls thus 
posing risk. No association was found in case of BDNF Val66Met polymorphism (Table 1). 
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None of the selected SNPs of BDNF and DRD2 showed deviation from Hardy-Weinberg 
equilibrium (HWE) in the control population. 
Our WD patient pool comprised 142 cases from eastern part of India (Kolkata) and 22 
individuals from the western part of India (Pune). To rule out the possibility of population 
bias, we run the analyses including all subjects as well as without the smaller western Indian 
sub-sample, with essentially the same results, with one exception: the Bonferroni-corrected 
association between the minor BDNF C270T allele and WD was no longer significant in the 
pure eastern Indian sample (Table 1).To further rule out the possibility of a skewed genotype 
distribution, which may have influenced the overall association with respect to WD, random 
Bootstrap sampling was carried out within the total WD patient dataset for replicates using 
82 samples each. At least eight of the ten replicates presented consistent associations for 
BDNF C270T and DRD2 Taq1A polymorphisms. 
The WD patients included in our study had variable ages of onset ranging from 1.5 to 30 
years. The patients also manifested various degrees and severity of hepatic and 
neurological features, such as serum ceruloplasmin level, urinary copper level, tremor, 
rigidity, dysarthria, cognitive impairment, and neuropsychiatric disturbances. Aiming to 
explain this heterogeneity, the BDNF and DRD2allele and genotype distributions were 
analyzed within WD patients. 
Our analysis revealed that the BDNF G allele encoding Valine [p–Value: 0.003; OR (95% CI) 
0.323 (0.517 – 0.657)] and GG (Val/Val) genotype [p – Value: 0.012; OR (95% CI) 0.315 
(0.134 – 0.734)] were significantly preponderant among WD patients with an age of onset 
≥10 years (Table 2). The WD patients carrying at least one BDNF A (Methionine) allele had 
an earlier age of onset (10.16 ± 4.72 years) compared to GG (Val/Val) genotype carriers 
(12.45 ± 5.4 years) (p= 0.015). In addition, the DRD2Taq1A the A1 allele [p – Value: 0.003; 
OR (95% CI) 2.226 (1.324 – 3.750)] and A1A1 genotype [p – Value: 0.018; OR (95% CI) 
3.500 (1.326 – 9.482)] were significantly more frequent among WD patients with rigidity 
compared to those without rigidity (Table 3). However, we did not find any significant 
difference in the age of onset between these two groups (11.84 ± 5.08 years vs. 10.94 ± 
4.65 years; p= 0.317). To investigate whether theDRD2 Taq1A polymorphism is regulating 
the rigidity as an independent phenotype we performed the analysis between WD patients 
with rigidity and WD patients without rigidity along with controls who did not have any 
personal or family history of neurological diseases. Interestingly the association also held 
true in this case (Supplementary Table 2).  
It is worth mentioning that since we did not have complete records for all the parameters for 
all the 164 patients, studies of the mentioned endophenotypes were carried out on a subset 
of WD patients based on the available clinical data (Supplementary Table 3).  
Except for the significant associations between BDNF Val66Met and age of onset and DRD2 
Taq1A and rigidity, no significant differences in allele or genotype frequencies were found 
with respect to any of the other clinical phenotypes tested. We did not observe any 
significant association for the selected variants comparing the WD cases and control with 
respect to gender (Supplementary Table 4). We did not find any significant association of 
any allele or genotype of BDNF C270T polymorphism with any clinical endophenotype 
studied amongst WD patients (data not shown). 
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Logistic regression analysis was performed within the patient sample with different genetic 
models (additive, dominant and recessive) while analyzing the association between the 
BDNF Val66Met and DRD2 Taq1A polymorphisms and age at onset of symptoms and 
rigidity respectively. The analysis revealed BDNF Val66Met polymorphism [Additive model p 
– value: 0.002, OR (95% CI) 0.3530 (0.1817 - 0.6858), Recessive model [p – value: 0.003, 
OR (95% CI) 0.3153 (0.1448 - 0.6864)] to be significantly associated with age of onset of the 
disease, while the DRD2 Taq1A polymorphism [Additive model p – value: 0.029, OR (95% 
CI) 1.6245 (1.0508 - 2.5115), recessive model p – value: 0.0307, OR (95% CI) 2.4261 
(1.0668 - 5.5178)] was significantly associated with rigidity among WD patients. The results 
of logistic regression analysis have been provided in the Tables 4 and 5.  
Discussion:   
Polymorphic variants in the modifier genes are known to influence the phenotype of a 
disease. Even for monogenic diseases like, cystic fibrosis, Rett syndrome and Wilson’s 
disease, a complex interaction between modifier genes has been reported to alter the 
expression, severity, and progression of the disease [Grillo et al, 2013, Gallati, 2014]. The 
clinical heterogeneity of WD has not been explained fully at its molecular level. Movement 
disorder phenotypes (tremor, rigidity, dystonia, and Parkinsonism) and neuropsychiatric 
disturbances (cognitive impairments, psychosis, aggressive behaviour, etc.) in WD have 
been reported to occur due to basal ganglia dysfunctions and/ or neurodegeneration in other 
related brain structures (Das and Ray, 2006). Previous investigators have highlighted the 
involvement of BDNF in neurodegenerative and neuropsychiatric diseases (Mizui et al, 
2014), implicating its potential involvement in WD. In the present study, we found that the C 
allele and CC genotype of BDNF C270T polymorphism play a protective function being 
significantly overrepresented among control individuals compared to WD patients. It is 
unlikely to get an overall association of BDNF C270T polymorphism with a monogenic 
disease. However, C270T polymorphism did not reveal any association with any 
endophenotype studied. Even, the mean age does not vary significantly between the groups 
bearing different genotype of this polymorphism. This result is similar to our previous finding, 
where APOE variants showed an overall association with the disease (Roy et al, 2017). 
Besides, other studies have also reported the association of DMT1 variant with the 
susceptibility of the disease (Przybyłkowski et al, 2014). In this context, it is likely that C 
allele or CC genotype of C270T polymorphism may act as a protective factor towards 
developing hepatic and neurological symptoms among WD patients. Increasing evidence 
suggests BDNF controls glucose metabolism in liver regulating gluconeogenic enzymes 
(Genzer et al, 2017). This evidence further supports the involvement of BDNF function 
outside the brain. A previous report from in-silico analysis revealed that the T allele of C270T 
polymorphism of BDNF could alter binding of transcription factors, i.e. histone H4 
transcription factor (HINFP) and Zic family member 3 (ZIC3) leading to deprived expression 
in the cortical region of brain (Catharius et al, 2005). However, we cannot rule out the 
possibility that the observed association between BDNF C270T and WD is due to mutation 
in another gene located in the same chromosome as BDNF or has emerged by chance.  
While studying the distribution of Val66Met polymorphism of BDNF, we found that G allele 
encoding Valine and GG (Val/Val) genotype were significantly more frequent among WD 
patients with an age of onset beyond 10 years. This possibly suggests that carriers of the G 
(Valine) allele and GG (Val/Val) genotype are less prone to develop WD symptoms at an 
earlier age. The Val66Met polymorphism is present in the pro-domain region of BDNF. 
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BDNF pro-peptide acts through p75 neurotrophin receptor facilitating long-term depression 
inducing apoptosis (Mizui et al, 2017). This may underlie the pathogenesis of 
neurodegeneration in WD. Previously, it has been reported that the Val66Met polymorphism 
impairs intracellular trafficking losing its interaction with the sortilin receptor complex (Mizui 
et al, 2014). In vitro cell based studies revealed that substitution of the methionine residue at 
this position leads to decreased distribution to the dendrites and impaired secretion (Egan et 
al, 2003). Functional magnetic resonance imaging (f-MRI) studies have shown that Val/Val 
carriers have a significantly higher level of hippocampal activation compared to Val/Met 
carriers. The BDNF Met allele affects glucose metabolism in brain regions like the 
hippocampus and the temporal parietal and occipital cortex (Xu et al, 2010). In mammals, 
BDNF is highly expressed in hippocampus, hence, neurodegeneration and cognitive 
dysfunctions observed among WD patients may be attributed to methionine substitution at 
this position (Mizui et al, 2017). The molecular mechanism underlying the earlier onset of 
WD symptoms remains elusive. Proper BDNF signalling in hepatocytes may promote fatty 
acid oxidation and glycogen storage (Genzer et al, 2017). Considering these evidences it is 
suggested that the presence of wild type G (Val) allele or GG (Val/Val) genotype may delay 
the onset of symptoms among WD patients.  
In this study the minor allele A1 and A1A1 genotype of Taq1A polymorphism of DRD2 gene 
were significantly preponderant among WD patients compared to healthy controls. Further, 
analyzing the distribution of allele and genotype for Taq1A polymorphism of DRD2 within 
WD patients, we found that A1 allele and A1A1 genotypes act as a risk factor for developing 
rigidity. The present study is in accordance with previous reports suggesting that A1 allele 
and/or A1A1 genotype may serve as a risk factor for developing neurodegenerative 
disorders like Parkinson’s and Alzheimer’s disease (Noble et al, 2003). Similar positive 
associations between the Taq1A polymorphism and alcohol dependence, addiction, 
schizophrenia and attention deficit hyperactivity disorder (ADHD) have been found (Noble, 
2000, Glatt et al, 2003, Rowe et al, 1999). In-vivo studies have also revealed association of 
the A1 allele with lower glucose metabolism in the dopaminergic neurons of the human brain 
(Rowe et al, 1999). The A1 allele of this polymorphism has been associated with lower 
dopamine D2 receptor expression in the striatum of post mortem brain (Noble et al, 2003). 
Most of the movement disorders and neuropsychiatric presentations of WD possibly occur 
due to defects in basal ganglia and prefrontal cortex. Radiological evidence and studies with 
post mortem brain revealed low dopamine D2receptor expression in the striatum of WD 
patients (Oder et al, 1996). This leads us to hypothesize that decreased DRD2 expression in 
the striatum of the carriers of the DRD2 Taq1 A1 allele and A1A1 genotype among WD 
patients underlie the cause of poor dopaminergic transmission resulting in rigidity symptoms. 
The mean ages of WD patients with and without rigidity did not vary significantly, which 
excludes the possibility of a prominent age factor to be involved in the development of 
rigidity among patients age 30 or below.  
Unavailability of clinical data for some of the patients restricted our analyses on smaller 
subsets of WD patients, which is a limitation of the study. Besides, we could not perform any 
further analysis based on association with the rarer clinical presentations, such as 
schizophrenia, depression and impulsiveness among these WD patients due to lack of 
follow-up.  
The patient pool included in this study contains heterogeneous mutation profiles including 
compound heterozygous conditions. Although the c.813C>A, Cys271X mutation in the 
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ATP7B gene is common among our patient cohort, the number of patients was too low to 
compare the effect of BDNF and DRD2 polymorphisms solely on the mutational background. 
Apart from prognostic benefits of studying modifier genes, it also leads us to the 
understanding of the etiology of the disease, where a single gene alone may not play a 
major role. Rather, the varying clinical manifestations are likely the result of complex 
interactions between different genes connected to biochemical pathways involved with the 
pathogenesis of the disease triggered by a single gene (ATP7B) in a monogenic disease. 
Conclusion:  
In conclusion our findings suggest that the BDNF C270T C allele may be associated with the 
occurrence of WD, the BDNF Val66Met Val allele and its homozygous genotype to serve as 
a protective factor delaying the age of onset. On the other hand in case of DRD2 Taq1A, A1 
allele and its homozygous genotype may be a risk factor for developing rigidity among 
patients with WD. However, our hypotheses need to be independently replicated. 
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Table 1: Frequency of allelic and genotypic distribution of BDNF and DRD2 polymorphisms among 
WD patients and controls 
Gene/ 
Polymorphism 
Allele/ 
Genotype 
WD Patients 
n = 164 (%) 
Control 
n = 270 (%) 
OR (95% CI) p - Value 
BDNF (Val66Met) 
G 254 (77.43) 407 (75.37) 
1.122 (0.801 – 1.573) 0.512a 
A 74 (22.56) 133 (24.63) 
GG 101 (61.58) 152 (56.29) 1.124 (0.822 – 1.886) 0.316 
GA 52 (31.70) 103 (38.15) 0.753 (0.489 – 1.158) 0.181 
AA 11 (6.70) 15 (5.56) 1.222 (0.509 – 2.907) 0.678 
BDNF 
(C270T) 
C 215 (65.54) 400 (74.07) 
0.666 (0.489 – 0.907) 0.027b* 
T 113 (34.45) 140 (25.92) 
CC 65 (39.63) 149 (55.18) 0.533 (0.352 – 0.806) 0.006 * 
CT 85 (51.83) 102 (37.78) 1.772 (1.174 – 2.677) 0.025 * 
TT 14 (8.54) 19 (7.04) 1.233 (0.566 – 2.669) 0.579 
DRD2 
(Taq1A) 
A2 201 (61.28) 379 (70.18) 
1.376 (1.018 – 1.859) 0.108 * 
A1 127 (38.71) 161 (29.81) 
A2A2 72(42.07) 132 (48.88) 0.818 (0.543 – 1.231) 0.323 
A2A1 63 (38.14) 115 (42.59) 0.841 (0.554 – 1.274) 0.421 
A1A1 29 (19.51) 23 (8.51) 2.307 (1.236 – 4.317) 0.018 * 
Gene/ 
Polymorphism 
Allele/ 
Genotype 
Eastern Indian 
WD Patients 
n = 142 (%) 
Control 
n = 270 (%) 
OR (95% CI) p - Value 
BDNF (Val66Met) 
G 220 (77.46) 407 (75.37) 
0.890 (0.624 – 1.268) 0.548a 
A 64 (22.53) 133 (24.63) 
GG 88 (61.97) 152 (56.29) 1.265 (0.818 – 1.959) 0.294 
GA 44 (30.98) 103 (38.15) 0.728 (0.461 – 1.147) 0.161 
AA 10 (7.04) 15 (5.56) 1.288 (0.521 – 3.143) 0.525 
BDNF 
(C270T) 
C 188 (66.19) 400 (74.07) 
0.685 (0.496 – 0.948) 0.057b* 
T 96 (33.81) 140 (25.92) 
CC 58 (40.84) 149 (55.18) 0.561 (0.364 – 0.864) 0.021* 
CT 72 (50.70) 102 (37.78) 1.694 (1.100 – 2.610) 0.036 * 
TT 12 (8.45) 19 (7.04) 1.219 (0.538 – 2.738) 0.695 
DRD2 
(Taq1A) 
A2 172 (60.56) 379 (70.18) 
1.533 (1.121 – 2.095) 0.018c* 
A1 112 (39.43) 161 (29.81) 
A2A2 57(40.14) 132 (48.88) 0.701 (0.455 – 1.080) 0.097 
A2A1 58 (40.84) 115 (42.59) 0.931 (0.603 – 1.435) 0.754 
A1A1 27 (19.01) 23 (8.51) 2.521 (1.331 – 4.784) 0.009 * 
 
WD, Wilson’s disease; BDNF, brain derived neurotrophic factor; DRD2, dopamine receptor D2; 
Val66Met, Valine66Methione; OR, Odds Ratio; 95% CI, 95% Confidence Interval. 
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p – Value < 0.05 considered statistically significant 
a, A vs G allele among WD patients and Controls for BDNF Val66Met 
b, Cvs T allele among WD patients and Controls for BDNF C270T 
c, A1 vs A2 allele among WD patients and Controls for DRD2TaqIA 
*Bonferroni adjusted p – values for multiple testing
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Table 2: Frequency of Allelic and genotypic distribution of BDNF Val66Met polymorphism among WD 
patients with early (≤ 10 years) and late onset (> 10 years) of symptoms 
Gene 
Allele/ 
Genotype 
Age of Onset 
OR (95% CI) p - Value 
Early Onset 
(≤ 10 years) 
n = 61 
Late Onset 
(> 10 years) 
n = 63 
BDNF 
Val66Met 
G 86 (70.49) 111 (88.09) 
0.323 (0.517 – 0.657) 0.003 ** 
A 36 (29.50) 15 (11.90) 
GG 32 (46.37) 49 (77.77) 0.315 (0.134 – 0.734) 0.012 ** 
GA 22 (31.88) 13 (20.63) 2.170 (0.905 – 5.247) 0.073 
AA 7 (10.14) 1 (1.58) 8.037 (0.941 – 179.42) 0.093 ** 
 
BDNF, brain derived neurotrophic factor; OR, Odds Ratio; CI, Confidence Interval, p– Value< 0.05 
considered statistically significant. 
**Bonferroni adjusted p – values for multiple testing 
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Table 3: Frequency of Allelic and genotypic distribution of DRD2/ANKK1Taq1A polymorphism among 
WD patients with and without rigidity 
 
WD, Wilson’s disease; OR, Odds Ratio; 95% CI, Confidence Interval; DRD2, dopamine receptor D2 
p – Value < 0.05 considered statistically significant 
***Bonferroni adjusted p – values for multiple testing 
Gene/ 
Polymorphism 
Allele/ 
Genotype 
Rigidity 
OR (95% CI) p - Value Present  
n = 69 (%) 
Absent 
n = 72 (%) 
DRD2/Taq1A 
A2 66 (47.83) 42 (29.16) 
2.226 (1.324 – 3.750) 0.003 *** 
A1 72 (52.17) 102 (70.83) 
A2A2 24 (34.78) 38 (52.77) 0.477 (0.228 – 0.992) 0.126 *** 
A2A1 24 (34,78) 26 (36.11) 0.994 (0.446 – 1.994) 1.000 
A1A1 21 (30.43) 8 (11.11) 3.500 (1.326 – 9.482) 0.018 *** 
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Table 4: Logistic regression analysis of independent variable to age of onset for WD patients 
 
BDNF, brain derived neurotrophic factor; OR, Odds Ratio; CI, Confidence Interval 
p – Value < 0.05 considered statistically significant. 
 
Independent 
Variables 
Model Genotype p – Value OR (95% CI) 
BDNF 
Val66Met 
Additive GG vs GA vs AA 0.002 0.3530 (0.1817 - 0.6858) 
Dominant GG + GA vs AA 0.054 0.1244 (0.0148 - 1.0437) 
Recessive GG vs GA + AA 0.003 0.3153 (0.1448 - 0.6864) 
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Table 5: Logistic regression analysis of independent variable to rigidity for WD patients 
 
DRD2, Dopamine Receptor D2; OR, Odds Ratio; CI, Confidence Interval 
p – Value < 0.05 considered statistically significant. 
 
Independent 
Variables 
Model Genotype p – Value OR (95% CI) 
DRD2 
Taq1A 
Additive GG vs GA vs AA 0.029 1.6245 (1.0508 - 2.5115) 
Dominant GA + AA vs GG 0.094 1.7736 (0.9008 - 3.4922) 
Recessive AA vs GA + GG 0.0307 2.4261 (1.0668 - 5.5178) 
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Supplementary Table 1: PCR and RFLP conditions for selected polymorphisms 
Gene Polymorphisms 
Amplicon 
length 
Primer Sequences PCR conditions 
Restriction 
Enzymes 
Digestion patterns 
BDNF 
rs 6265/ G196A/ 
Val66Met 
615 bp 
 Forward Primer :  
5’ AAACATCCGAGGACAAGGT3’ 
Reverse Primer :  
5’GCCAGCCAATTCTCTTTTTG3’ 
56 ºC (30’-30’-
30’) X 35 
cycles 
Pml I 
G = 490 + 125 bp 
 
A = 615 bp 
rs 56164415/ C270T 313 bp 
Forward Primer : 
5’ GGGGGCTTTAATGAGACACC 3’ 
Reverse Primer : 
5’ GGAGAAAACTCCCCAAGAG3’ 
54 ºC (30’-30’-
30’) X 35 
cycles 
Hpy188III 
C = 313 bp 
 
T = 189 + 124 bp 
DRD2 rs1800497/ Taq1A 338 bp 
Forward Primer: 
5’GAGGAGCACCTTCCTGAGTG 3’ 
Reverse Primer:  
5’ CTGGGATTACAGACGTGAG3’ 
66º - 56º C 
touchdown; 35 
cycles 
Taq I 
G = 132 +  206 bp 
 
A = 338 bp 
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Supplementary Table 2: Frequency of Allelic and genotypic distribution of DRD2/ANKK1 Taq1A 
polymorphism among WD patients with rigidity and WD patients without rigidity along with the healthy 
controls.  
 
WD, Wilson’s disease; OR, Odds Ratio; CI, Confidence Interval; DRD2, dopamine receptor D2 
¥Bonferroni adjusted p- values for multiple testing. 
Gene/ 
Polymorphism 
Allele/ 
Genotype 
Rigidity 
OR (95% CI) p - Value Present  
n = 69 (%) 
Absent 
n = 342 (%) 
DRD2/Taq1A 
A2 66 (47.83) 421 (61.54) 
1.746 (1.189 – 2.565) 0.009¥ 
A1 72 (52.17) 263 (38.45) 
A2A2 24 (34.78) 170 (49.70) 0.540 (0.304 – 0.955) 0.075¥ 
A2A1 24 (34,78) 141 (41.22) 0.760 (0.427 – 1.347) 0.348 
A1A1 21 (30.43) 31 (9.06) 4.389 (2.225 – 8.645) 0.000003¥ 
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Supplementary table 4: Allele and genotype distribution for BDNF and DRD2 polymorphisms among 
the WD patients and Control with respect to Gender. 
 
WD, Wilson’s disease; OR, Odds Ratio; 95% CI, Confidence Interval; BDNF, brain derived 
neurotrophic factor; DRD2, dopamine receptor D2 
p – Value < 0.05 considered statistically significant 
ŧBonferroni adjusted p – value for multiple testing 
Gene/ 
Polymorphism 
Allele/ 
Genotype 
WD Patients 
Male 
n = 104 
Control 
Male 
n = 212 
OR (95% CI) p - value 
BDNF 
Val66Met 
G 165 (79.32) 322 (75.94) 
0.823 (0.539 – 1.254) 0.366 
A 43 (20.67) 102 (24.05) 
GG 70 (67.30) 124 (58.49) 1.490 (0.885 - 2.513) 0.140 
GA 25 (24.03) 75 (35.37) 0.566 (0.322 – 0.993) 0.200 ŧ 
 AA 9 (8.65) 13 (6.132) 1.450 (0.549 – 3.783) 0.481 
BDNF 
C270T 
C 134 (64.42) 314 (74.05) 
0.745 (0.506 – 1.097) 0.125 
T 74 (35.57) 110 (25.94) 
CC 41(39.42) 117 (55.18) 0.528 (0.319 – 0.875) 0.060 ŧ 
CT 52 (50.0) 80 (37.73) 1.650 (0.999 – 2.727) 0.200 ŧ 
TT 11 (10.57) 15 (7.07) 1.553 (0.637 – 3.756) 0.285 
DRD2 
Taq1A 
A2 128 (61.53) 292 (68.86) 
1.383 (0.963 – 1.985) 0.073 
A1 80 (38.46) 132 (31.13) 
A2A2 45 (43.27) 101 (47.64) 0.838 (0.308 – 1.381) 0.474 
A2A1 38 (36.53) 90 (42.45) 0.780 (0.467 – 1.301) 0.332 
A1A1 21 (20.19) 21 (9.90) 2.301 (1.135 – 4.667) 0.070 ŧ 
Gene/ 
Polymorphism 
Allele/ 
Genotype 
WD Patients 
Female 
n = 60 
Control 
Female 
n = 58 
OR (95% CI) p - value 
BDNF 
Val66Met 
G 89 (74.16) 85 (73.27) 
0.955 (0.514 – 1.776) 0.884 
A 31 (25.83) 31 (26.72) 
GG 31 (51.67) 29 (50.0) 1.069 (0.487 – 2.347) 1.000 
GA 27 (45.0) 27 (46.55) 0.939 (0.427 – 2.067) 1.000 
AA 2 (3.33) 2 (3.45) 0.966 (0.093 -  10.018) 1.000 
BDNF 
C270T 
C 81 (67.50) 86 (74.13) 
1.380 (0.756 – 2.525) 0.317 
T 39 (32.50) 30 (25.86) 
CC 24 (40.0) 32 (55.17) 0.542 (0.244 – 1.199) 0.140 
CT 33 (55.0) 22 (37.93) 2.000 (0.900 – 4.467) 0.068 
TT 3 (5.0) 4 (6.89) 0.711 (0.119 – 3.997) 0.715 
DRD2 
Taq1A 
A2 79 (65.83) 87 (75.0) 
1.557 (0.852 – 2.849) 0.154 
A1 41 (34.16) 29 (25.0) 
A2A2 27 (45.0) 31 (53.45) 0.713 (0.323 – 1.567) 0.461 
A2A1 25 (41.66) 25 (43.10) 0.943 (0.425 – 2.089) 1.000 
A1A1 8 (13.33) 2 (3.44) 4.308 (0.790 – 30.908) 0.095 
